Dandekar Atul's Form 4 filing
Maze Therapeutics, Inc. (MAZE) · filed Sep 4, 2026
- Accession no.
- 0002050167-26-000027
- Filed
- Sep 4, 2026, 4:25 PM ET
- Trade date
- Sep 2-3, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $168.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dandekar AtulCIK 0002050167 | Officer (CSBO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Common Stock | SSaleDisposed | −2,800 | $26.38 | −$73,852.8 | 35,950 | Direct | |
| Sep 2, 2026 | Common Stock | SSaleDisposed | −391 | $27.12 | −$10,604.35 | 35,559 | Direct | |
| Sep 3, 2026 | Common Stock | SSaleDisposed | −3,207 | $26.01 | −$83,424.65 | 32,352 | Direct | |
| Sep 3, 2026 | Common Stock | SSaleDisposed | −36 | $25.81 | −$929.16 | 32,316 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.